Immunodeficiency following hereditary defective response to Epstein-Barr virus

PheWeb

D3_IMMUDEFPOSTEBV

No definition available.

Endpoint definition

↥

FinnGen phenotype data

392423 individuals

Apply sex-specific rule None

392423

Check conditions None

392423

Check pre-conditions, main-only, mode, registry filters

Hospital Discharge: ICD-10 D82.3

Cause of death: ICD-10 D82.3

2 out of 7 registries used, show all original rules.

Check minimum number of events None

Include endpoints None

Remove individuals based on genotype QC

D3_IMMUDEFPOSTEBV

Control definitions

Control exclude D3_IMMUNEMECHANISM

Extra metadata

Level in the ICD hierarchy 4

First used in FinnGen datafreeze DF2

Parent code in ICD-10 D82

Name in latin Deficientia immunalis cum responso defectivo contra agentem viralem Epstein-Barr

NAME	D3_IMMUDEFPOSTEBV
CONTROL_EXCLUDE	D3_IMMUNEMECHANISM
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	D823
HD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	D823
COD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Not enough data for upset plot.

Not enough data for upset table.

Similar endpoints

↥

List of similar endpoints to Immunodeficiency following hereditary defective response to Epstein-Barr virus based on the number of shared cases.

Broader endpoints:

None

Narrower endpoints:

None

Show all endpoint correlations

Summary Statistics

↥

Key figures

	All	Female	Male
Number of individuals	-	-	-
Unadjusted prevalence (%)	-	-	-
Mean age at first event (years)	-	-	-

Mortality

Follow-up	Absolute risk	HR [95% CI]	p	N
1998–2019	-	-	-	-
15 years	-	-	-	-
5 years	-	-	-	-
1 year	-	-	-	-

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: D3_IMMUDEFPOSTEBV – Immunodeficiency following hereditary defective response to Epstein-Barr virus
GWS hits:

Survival analyses between endpoints

↥

Not a core endpoint, no data to show.

Drugs most likely to be purchased after Immunodeficiency following hereditary defective response to Epstein-Barr virus

↥

Endpoint not on priority list, no data to show.

≡ Risteys

R9

R8

R7

R6

R5

R4

R3